CASP1 and colitis: Inhibition of acute colitis (decreases CASP1 expression and MPO, MDA, and iNOS levels; increases Nrf2 expression; prevents the degradation of Nrf2 via ubiquitination by blocking the interaction between Cullin3 and Keap1; and increases GSH and SOD levels)